Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a non-coding RNA, classified as a novel transcript found in the genomic region antisense to the CEP295NL and TIMP2 genes. It does not encode a protein. Antisense RNAs are transcripts generated from the opposite DNA strand of a coding gene; they can modulate gene expression through epigenetic and post-transcriptional mechanisms, such as altering chromatin structure or interfering with sense transcription[3]. Based on current evidence, this transcript is not established as a therapeutic target (such as a receptor, enzyme, transporter, etc.), and its biological function is not well characterized. There are no known associated aliases, molecular families beyond "non-coding RNA/antisense RNA," disease roles, or interactions with drugs. The available information is incomplete and mostly descriptive of its genomic context; therefore, it should not be treated as a validated or characterized therapeutic target at present[1]. Key considerations: - The entry represents a non-coding/annotated antisense RNA, not a conventional protein target[1]. - It is not currently considered a druggable or disease-relevant target, nor does it have established roles in therapy or diagnostics[1][3]. - The Entrez symbol “ENSG00000305285” is an Ensembl gene identifier and is not a canonical abbreviation for a receptor or drug target. - This target is incomplete for drug development criteria: missing information about structure, function, and disease association. If further annotated biological roles or disease associations are identified in the future, its status may change, but as of now, it does not fulfill the requirements as a standard therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to CEP295NL and TIMP2 (ENSG00000305285).